Progress Toward Poliomyelitis Eradication - Worldwide, January 2021-March 2023.


Journal

MMWR. Morbidity and mortality weekly report
ISSN: 1545-861X
Titre abrégé: MMWR Morb Mortal Wkly Rep
Pays: United States
ID NLM: 7802429

Informations de publication

Date de publication:
12 May 2023
Historique:
medline: 15 5 2023
pubmed: 11 5 2023
entrez: 11 5 2023
Statut: epublish

Résumé

Since the World Health Assembly established the Global Polio Eradication Initiative (GPEI) in 1988, two of the three wild poliovirus (WPV) serotypes (types 2 and 3) have been eradicated, and global WPV cases have decreased by more than 99.9%. Afghanistan and Pakistan remain the only countries where indigenous WPV type 1 (WPV1) transmission has not been interrupted. This report summarizes progress toward global polio eradication during January 1, 2021-March 31, 2023, and updates previous reports (1,2). In 2022, Afghanistan and Pakistan reported 22 WPV1 cases, compared with five in 2021; as of May 5, 2023, a single WPV1 case was reported in Pakistan in 2023. A WPV1 case was reported on the African continent for the first time since 2016, when officials in Malawi confirmed a WPV1 case in a child with paralysis onset in November 2021; neighboring Mozambique subsequently reported eight genetically linked cases. Outbreaks of polio caused by circulating vaccine-derived polioviruses (cVDPVs) can occur when oral poliovirus vaccine (OPV) strains circulate for a prolonged time in underimmunized populations, allowing reversion to neurovirulence (3). A total of 859 cVDPV cases occurred during 2022, an increase of 23% from 698 cases in 2021. cVDPVs were detected in areas where poliovirus transmission had long been eliminated (including in Canada, Israel, the United Kingdom, and the United States). In addition, cocirculation of multiple poliovirus types occurred in multiple countries globally (including Democratic Republic of the Congo [DRC], Israel, Malawi, Mozambique, Republic of the Congo, and Yemen). The 2022-2026 GPEI strategic plan targeted the goal of detecting the last cases of WPV1 and cVDPV in 2023 (4). The current global epidemiology of poliovirus transmission makes the likelihood of meeting this target date unlikely. The detections of poliovirus (WPV1 and cVDPVs) in areas where it had been previously eliminated underscore the threat of continued poliovirus spread to any area where there is insufficient vaccination to poliovirus (3). Mass vaccination and surveillance should be further enhanced in areas of transmission to interrupt poliovirus transmission and to end the global threat of paralytic polio in children.

Identifiants

pubmed: 37167156
doi: 10.15585/mmwr.mm7219a3
pmc: PMC10208367
doi:

Substances chimiques

Poliovirus Vaccine, Oral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

517-522

Déclaration de conflit d'intérêts

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Références

MMWR Morb Mortal Wkly Rep. 2022 Jun 17;71(24):786-790
pubmed: 35709073
MMWR Morb Mortal Wkly Rep. 2022 May 13;71(19):650-655
pubmed: 35552352
MMWR Morb Mortal Wkly Rep. 2023 Apr 14;72(15):391-397
pubmed: 37053125
Vaccine. 2023 Apr 6;41 Suppl 1:A122-A127
pubmed: 35307230
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1129-1135
pubmed: 34437527
MMWR Morb Mortal Wkly Rep. 2023 Apr 07;72(14):366-371
pubmed: 37022974
MMWR Morb Mortal Wkly Rep. 2022 Dec 09;71(49):1541-1546
pubmed: 36480464
MMWR Morb Mortal Wkly Rep. 2022 Oct 21;71(42):1313-1318
pubmed: 36264783

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH